Search

  • HOME
  • Search
Reply to Correspondence
Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
Mirko Zoncapè, Emmanuel A. Tsochatzis
Clin Mol Hepatol. 2025;31(1):e117-e118.   Published online November 11, 2024
View: 439   Download: 15
Correspondence
Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee
Clin Mol Hepatol. 2025;31(1):e110-e112.   Published online October 2, 2024
View: 638   Download: 42
Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”
Gi-Ae Kim, Seung Won Choi, Young-Suk Lim
Clin Mol Hepatol. 2025;31(1):e108-e109.   Published online August 5, 2024
View: 712   Download: 30
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
Hee Yeon Kim, Miyoung Choi, Dae Won Jun
Clin Mol Hepatol. 2025;31(1):e105-e107.   Published online November 4, 2024
View: 414   Download: 19
Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee
Clin Mol Hepatol. 2025;31(1):e84-e86.   Published online October 7, 2024
View: 574   Download: 28
Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee
Clin Mol Hepatol. 2025;31(1):e81-e83.   Published online October 7, 2024
View: 628   Download: 32  Crossref: 1
Correspondence to editorial on: “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”
Satya Priya Sharma, Ki Tae Suk
Clin Mol Hepatol. 2025;31(1):e74-e77.   Published online October 15, 2024
View: 802   Download: 42
2035
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
Hee Yeon Kim, Miyoung Choi, Dae Won Jun
Clin Mol Hepatol. 2025;31(1):e48-e51.   Published online September 11, 2024
View: 534   Download: 23
Letter to the Editor
Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes
Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen
Clin Mol Hepatol. 2025;31(1):e35-e38.   Published online September 20, 2024
View: 694   Download: 59
Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”
Wei Feng, Qile Wang, Qingwang Ye
Clin Mol Hepatol. 2025;31(1):e21-e22.   Published online October 11, 2024
View: 633   Download: 26
Snapshot
1993
Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues
Clara Meda, Arianna Dolce, Sara Della Torre
Clin Mol Hepatol. 2025;31(1):327-332.   Published online August 5, 2024
View: 666   Download: 70
Original Article
2102
Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis
Anja Tiede, Lena Stockhoff, Zhaoli Liu, Hannah Rieland, Jim B. Mauz, Valerie Ohlendorf, Birgit Bremer, Jennifer Witt, Anke Kraft, Markus Cornberg, Jan B. Hinrichs, Bernhard C. Meyer, Heiner Wedemeyer, Cheng-Jian Xu, Christine S. Falk, Benjamin Maasoumy
Clin Mol Hepatol. 2025;31(1):240-255.   Published online November 21, 2024
View: 934   Download: 154  Crossref: 1
2101
Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis
Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2025;31(1):227-239.   Published online November 14, 2024
View: 1040   Download: 93
2051
USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination
Sha Hu, Zhouxiang Wang, Kun Zhu, Hongjie Shi, Fang Qin, Tuo Zhang, Song tian, Yanxiao Ji, Jianqing Zhang, Juanjuan Qin, Zhigang She, Xiaojing Zhang, Peng Zhang, Hongliang Li
Clin Mol Hepatol. 2025;31(1):147-165.   Published online October 2, 2024
View: 2263   Download: 514
2049
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation
Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi
Clin Mol Hepatol. 2025;31(1):131-146.   Published online October 2, 2024
View: 1044   Download: 161
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X


Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 188
TOTAL : 2442335
Close layer